Download PDF
Exp Clin Endocrinol Diabetes 2003; 111(2): 97-103
DOI: 10.1055/s-2003-39237
Article

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes

T. Forst 1 , J. W. Eriksson 2 , H.-J. Strotmann 3 , S. Bai 4 , R. Brunelle 4 , K. S. Gulliya 4 , S. Gack 4 , U. Gudat 4
  • 1Institute for Clinical Research and Development, Mainz, Germany
  • 2Metabolenheten - Medicinkliniken, Umeå, Sweden
  • 3Center for Diabetes and Nutritional Medicine, Rotenburg, Germany
  • 4Eli Lilly & Company, Indianapolis, USA
Further Information

Publication History

Received: February 14, 2002 First decision: March 21, 2002

Accepted: September 24, 2002

Publication Date:
14 May 2003 (online)

Also available at
    Permissions and Reprints

Abstract

The efficacy and safety of the preprandial injection of insulin lispro was compared with the oral administration of glibenclamide in patients with early type 2 diabetes. In this open-label, multicenter study, 143 patients with a glucagon-stimulated increase in C-peptide of at least 0.4 nmol/L were randomized to receive preprandial insulin lispro (LP) or glibenclamide (GB) for 26 weeks. Seventy-five patients received LP (51 male/24 female; age 40 to 70 years, duration of diabetes 4.4 ± 2.9 years) and 68 patients received GB (39 male/29 female; age 39 to 70 years; duration of diabetes 4.3 ± 3.4 years). After 12 weeks, mean 90 minute blood glucose excursions were 0.9 ± 1.0 mmol/L for LP and 1.8 ± 1.2 mmol/L for GB (p < 0.0001). After 24 weeks, mean blood glucose excursions were 1.0 ± 1.1 mmol/L for LP and 1.7 ± 1.2 mmol/L for GB (p = 0.002). Body weight decreased slightly from 87.2 ± 2.3 to 86.5 ± 12.2 kg in the LP group and increased from 84.1 ± 13.7 to 84.4 ± 13.3 kg in the GB group. LP versus GB induced changes from baseline to endpoint in fasting C-peptide (nmol/L), proinsulin and insulin levels (pmol/L) were - 0.2 ± 0.4 versus - 0.1 ± 0.6 (p = 0.04), - 11.2 ± 26.0 versus - 1.1 ± 17.3 (p = 0.03), and - 27.8 ± 147.4 versus + 32.6 ± 286.2 (not significant), respectively. HbA1c at baseline was 7.5 ± 1.0 % for LP and 7.7 ± 1.2 % for GB and did not change significantly in either group during the investigation. No significant difference was observed between the groups with respect to hypoglycemic episodes. Treatment with LP improved postprandial blood glucose control more than GB without increasing body weight or hypoglycemic episodes. In addition, use of LP was associated with a decrease in fasting C-peptide and proinsulin levels, suggesting a potential down regulation of endogenous insulin production and improved proinsulin processing efficiency.

Key words

Early diabetes type 2 - Insulin lispro - Glibenclamide - C-peptide - Proinsulin - HbA1c

References

  • 1 Agardh C D, Nilsson-Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus.  Diabetes Care. 1982;  5 322-325
    PubMedGoogle Scholar
  • 2 Andrews W J, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven G M. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.  Diabetes. 1984;  33 634-642
    CrossrefPubMedGoogle Scholar
  • 3 Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer A F. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro.  Diabetologia. 2001;  44 188-195
    CrossrefPubMedGoogle Scholar
  • 4 Ayo S H, Radnik R, Garoni J A, Troyer D A, Kreisberg J I. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures.  Am J Physiol. 1991;  261 F571-F577
    PubMedGoogle Scholar
  • 5 Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study.  Diabetes Care. 1998;  21 1236-1239
    CrossrefPubMedGoogle Scholar
  • 6 Bastyr III E J, Johnson M E, Trautmann M E, Anderson Jr. J H. Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure.  Clin Ther. 1999;  21 1703-1714
    CrossrefPubMedGoogle Scholar
  • 7 Bowsher R R, Wolny J D, Frank B H. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum.  Diabetes. 1992;  41 1084-1090
    PubMedGoogle Scholar
  • 8 Bruce D G, Chisholm D J, Storlien L H, Borkman M, Kraegen E W. Meal-time intranasal insulin delivery in type 2 diabetes.  Diabet Med. 1991;  8 366-370
    PubMedGoogle Scholar
  • 9 Bruce D G, Chisholm D J, Storlien L H, Kraegen E W. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes.  Diabetes. 1988;  37 736-744
    PubMedGoogle Scholar
  • 10 Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M C, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.  Diabetes. 1999;  48 99-105
    CrossrefPubMedGoogle Scholar
  • 11 Calles-Escandon J, Robbins D C. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose.  Diabetes. 1987;  36 1167-1172
    PubMedGoogle Scholar
  • 12 Ceriello A. Acute hyperglycaemia and oxidative stress generation.  Diabet Med. 1997;  14 (Suppl 3) S45-S49
    CrossrefPubMedGoogle Scholar
  • 13 Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E. Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients: the possible role of metabolic control and oxidative stress.  Metabolism. 1996 a;  45 498-501
    CrossrefPubMedGoogle Scholar
  • 14 Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, Pirisi M, Falleti E, Bartoli E. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress.  Diabetes. 1995;  44 924-928
    PubMedGoogle Scholar
  • 15 Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose.  Diabetologia. 1996 b;  39 469-473
    CrossrefPubMedGoogle Scholar
  • 16 de Vegt F, Dekker J M, Ruhe H G, Stehouwer C D, Nijpels G, Bouter L M, Heine R J. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study.  Diabetologia. 1999;  42 926-931
    CrossrefPubMedGoogle Scholar
  • 17 DeFronzo R A. The effect of insulin on renal sodium metabolism. A review with clinical implications.  Diabetologia. 1981;  21 165-171
    PubMedGoogle Scholar
  • 18 Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.  Diabetes Metab Res Rev. 2001;  17 164-174
    CrossrefPubMedGoogle Scholar
  • 19 Feinglos M N, Thacker C H, English J, Bethel M A, Lane J D. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.  Diabetes Care. 1997;  20 1539-1542
    PubMedGoogle Scholar
  • 20 Garvey W T, Olefsky J M, Griffin J, Hamman R F, Kolterman O G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.  Diabetes. 1985;  34 222-234
    CrossrefPubMedGoogle Scholar
  • 21 Gerich J E. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?.  Diabetes. 2002;  51 (Suppl 1) S117-S121
    CrossrefPubMedGoogle Scholar
  • 22 Hanefeld M, Fischer S, Julius S, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch H J, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11 year follow up.  Diabetologia. 1996;  39 1577-1583
    CrossrefPubMedGoogle Scholar
  • 23 Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.  Atherosclerosis. 1999;  144 229-235
    CrossrefPubMedGoogle Scholar
  • 24 Hanley A J, McKeown-Eyssen G, Harris S B, Hegele R A, Wolever T M, Kwan J, Connelly P W, Zinman B. Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition.  Diabetes Care. 2001;  24 1240-1247
    PubMedGoogle Scholar
  • 25 Heinemann L, Heise T, Wahl L C, Trautmann M E, Ampudia J, Starke A A, Berger M. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.  Diabet Med. 1996;  13 625-629
    CrossrefPubMedGoogle Scholar
  • 26 Hosker J P, Burnett M A, Matthews D R, Turner R C. Suppression of insulin secretion by falling plasma glucose levels is impaired in type 2 diabetes.  Diabet Med. 1988;  5 856-860
    PubMedGoogle Scholar
  • 27 Howey D C, Bowsher R R, Brunelle R L, Woodworth J R. [Lys(B28), Pro(B29)]-human insulin.  Diabetes. 1994;  43 396-402
    CrossrefPubMedGoogle Scholar
  • 28 Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.  Diabetes Care. 1997;  20 1353-1356
    CrossrefPubMedGoogle Scholar
  • 29 Jain S K, Nagi D K, Slavin B M, Lumb P J, Yudkin J S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.  Diabet Med. 1993;  10 27-32
    CrossrefPubMedGoogle Scholar
  • 30 Kawamori R, Bando K, Yamasaki Y, Kubota M, Watarai T, Iwama N, Shichiri M, Kamada T. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.  Diabetes Care. 1989;  12 680-685
    PubMedGoogle Scholar
  • 31 Kraegen E W, Young J D, George E P, Lazarus L. Oscillations in blood glucose and insulin after oral glucose.  Horm Metab Res. 1972;  4 409-413
    PubMedGoogle Scholar
  • 32 Lefebvre P, Scheen A J. The postprandial state and risk of cardiovascular disease.  Diabet Med. 1998;  15 S63-S68
    CrossrefPubMedGoogle Scholar
  • 33 Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?.  Diabetologia. 1996;  39 503-514
    PubMedGoogle Scholar
  • 34 Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.  BMJ. 1997;  314 1512-1515
    CrossrefPubMedGoogle Scholar
  • 35 Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction.  Eur Heart J. 1996;  17 1337-1344
    CrossrefPubMedGoogle Scholar
  • 36 Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.  Diabetes. 1990;  39 1381-1390
    PubMedGoogle Scholar
  • 37 Muhlhauser I, Sawicki P T, Berger M. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.  Diabetologia. 1997;  40 1492-1493
    CrossrefPubMedGoogle Scholar
  • 38 Nagi D K, Hendra T J, Ryle A J, Cooper T M, Temple R C, Clark P M, Schneider A E, Hales C N, Yudkin J S. The relationships of concentrations of insulin, intact proinsulin and 32 - 33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects [see comments].  Diabetologia. 1990;  33 532-537
    CrossrefPubMedGoogle Scholar
  • 39 Owens D R, Jones M K, Hayes T M, Heding L G, Alberti K G, Home P D, Burrin J M. Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin.  Lancet. 1981;  2 118-122
    PubMedGoogle Scholar
  • 40 Panahloo A, Mohamed-Ali V, Andres C, Denver A E, Yudkin J S. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes.  Metabolism. 1998;  47 637-643
    CrossrefPubMedGoogle Scholar
  • 41 Paterson K R, Wilson M, Kesson C M, Buchan M, Roberts M, Reith S B, Davidson E. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy.  Diabet Med. 1991;  8 40-43
    PubMedGoogle Scholar
  • 42 Poitout V, Robertson R P. An integrated view of beta-cell dysfunction in type-II diabetes.  Annu Rev Med. 1996;  47 69-83
    CrossrefPubMedGoogle Scholar
  • 43 Polonsky K S. Non-insulin dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance.  N Engl J Med. 1996;  334 777-783
    CrossrefPubMedGoogle Scholar
  • 44 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
    CrossrefPubMedGoogle Scholar
  • 45 Robbins D C, Jaspan J, Vasquez B, Van Cauter E. Biphasic patterns of peripheral insulin and glucose levels after lunch in normal subjects.  Diabetes Care. 1987;  10 293-299
    PubMedGoogle Scholar
  • 46 Shaw J E, Hodge A M, de Courten M, Chitson P, Zimmet P Z. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality [published erratum appears in Diabetologia 1999; 42: 1444].  Diabetologia. 1999;  42 1050-1054
    CrossrefPubMedGoogle Scholar
  • 47 Temelkova-Kurktschiev T S, Koehler C, Leonhardt W, Schaper F, Henkel E, Siegert G, Hanefeld M. Increased intima-medial thickness in newly detected type 2 diabetes: risk factors.  Diabetes Care. 1999;  22 333-338
    CrossrefPubMedGoogle Scholar
  • 48 Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose.  Diabetes Care. 1999;  22 920-924
    CrossrefPubMedGoogle Scholar
  • 49 Torlone E, Fanelli C, Rambotti A M, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM.  Diabetologia. 1994;  37 713-720
    PubMedGoogle Scholar
  • 50 Turner R C, McCarthy S T, Holman R R, Harris E. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes.  Br Med J. 1976;  1 1252-1254
    PubMedGoogle Scholar
  • 51 Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus.  Diabetologia. 1988;  31 355-360
    PubMedGoogle Scholar
  • 52 Yudkin J S. Circulating proinsulin-like molecules.  J Diabetes Complications. 1993;  7 113-123
    CrossrefPubMedGoogle Scholar
  • 53 Yudkin J S, May M, Elwood P, Yarnell J W, Greenwood R, Davey S G. Concentrations of proinsulin-like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study.  Diabetologia. 2002;  45 327-336
    CrossrefPubMedGoogle Scholar

Priv. Doz. Dr. Thomas Forst

Institute for Clinical Research and Development

Parcusstraße 8

55116 Mainz

Germany

Email: Thomasf@ikfe.de

      >